Table 2 Univariate and multivariate analyses of clinicopathological characteristics, miR-195-5p, and YAP1 with overall survival in TCGA COAD cohort and independent validation cohort

 Gender(male vs. female)

1.938(1.065–3.526)

0.030

2.512(1.321–4.775)

0.005

 Age, years (≥median vs. < median)

1.591(0.843–3.003)

0.152

 Nodes count (12 or more vs. fewer than 12)

0.726(0.402–1.309)

0.287

 Lymphatic invasion (present vs. absent)

2.171(1.238–3.809)

0.007

1.453(0.572–3.694)

0.432

 Pathologic M stage (present vs. absent)

3.060(1.652–5.667)

0.001

1.969(0.988–3.924)

0.034

 TNM stage (III and IV vs. I and II)

2.099(1.185–3.717)

0.011

1.206(0.573–2.536)

0.622

 Vascular invasion (present vs. absent)

2.400(1.318–4.372)

0.004

1.660(0.719–3.830)

0.235

 Preoperative CEA level

(≥5 μg/mL vs. <5 μg/mL)

0.982(0.542–1.780)

0.953

 Hsa-miR-195 (≥median vs. < median)

0.488(0.262–0.910)

0.023

0.419(0.214–0.819)

0.011

 YAP1 (≥median vs. < median)

2.022(1.120–3.652)

0.019

1.379(0.714–2.664)

0.339

 Gender(male vs. female)

0.879(0.494–1.564)

0.661

 Age, years (≥median vs. < median)

0.823(0.458–1.478)

0.514

 Nodes count (12 or more vs. fewer than 12)

1.323(0.724–2.418)

0.363

 Lymphatic invasion (present vs. absent)

1.542(0.852–2.790)

0.153

 Pathologic M stage (present vs. absent)

16.910(5.793–49.361)

<0.001

4.140(2.825–5.442)

0.001

 TNM stage (III and IV vs. I and II)

1.542(0.852–2.789)

0.153

 Vascular invasion (present vs. absent)

1.060(0.541–2.075)

0.866

 Preoperative CEA level

(≥5 μg/mL vs. <5 μg/mL)

0.893(0.506-1.573)

0.695

 Hsa-miR-195 (≥median vs. < median)

0.526(0.294–0.941)

0.031

0.704(0.344–0.875)

0.044

 YAP1 (≥median vs. < median)

1.969(1.092–3.547)

0.024

1.476(0.623–3.497)

0.377